Fundamentals in Urology Webcast (2016): Uro-Ethics
The Fundamentals in Urology course is designed to apply basic science knowledge and principles in development of treatment algorithms. This 4-day course will provide attendees with valuable skills in developing a rational methodological approach to application of knowledge which will contribute to positive outcomes for patients. Attendees will discover the importance of the study of basic sciences and how it transfers into the lifelong learning process and medical practice. This course is designed to ensure a fundamental knowledge of the "why" behind a broad expanse of general urologic conditions. A thorough knowledge of the basic science behind the treatments will allow for better counseling and education of patients by all clinical urologic practitioners.
Target Audience
This course is designed for:
- Urology Residents
- Allied Health Professionals
Learning Objectives
At the conclusion of this webcast, participants will be able to:
- Identify specific applications of basic science knowledge and principles in development of treatment methods
- Develop a scientific and methodological approach to the application of knowledge gained at the conference that is consistent with AUA guidelines and best practices
- Compare newly published findings and their impact on medical practice and patient care
- Transfer continuing study of basic sciences into lifelong learning process and medical practice
- Articulate the rationale for their treatment approach concisely to the patient and modify the treatment plan as circumstances change
Faculty Disclosures:
Name | Company | Role | Financial |
Trinity J. Bivalacqua, MD | heat biologic | Scientific Study or Trial | No |
photocure | Scientific Study or Trial | No | |
Raymond A. Costabile, MD | Lilly/Icos | Consultant or Advisor, Scientific Study or Trial | No |
Vivus | Scientific Study or Trial | No | |
Paul L. Crispen, M.D. | Nothing to disclose. | ||
Robert J. Evans, MD | allergan | Scientific Study or Trial | Yes |
urigen | Investment Interest | Yes | |
allergan | Scientific Study or Trial | Yes | |
TARIS | Scientific Study or Trial | Yes | |
aquinox | Consultant or Advisor, Scientific Study or Trial | Yes | |
Patricio C. Gargollo, MD | Nothing to disclose. | ||
Leonard G. Gomella, MD | Astellas | Consultant or Advisor | Yes |
Janssen | Consultant or Advisor | Yes | |
Dendreon | Consultant or Advisor, Scientific Study or Trial | Yes | |
Wolters Kluwer | Health Publishing | Yes | |
McGraw Hill | Health Publishing | Yes | |
Merck Manual | Health Publishing | Yes | |
Canadian Journal of Urology | Health Publishing | Yes | |
MDx Health | Consultant or Advisor | Yes | |
Merck Pharmaceuticals | Consultant or Advisor | Yes | |
Bayer | Consultant or Advisor | Yes | |
Mikel L. Gray, Ph.D. | Laborie Medical | Meeting Participant or Lecturer | Yes |
3M Inc. | Consultant or Advisor | Yes | |
C.D. Anthony Herndon, MD, FAAP, FACS | Nothing to disclose. | ||
Adam Philip Klausner, MD | Nothing to disclose. | ||
Tracey Krupski, MD | Argos | Scientific Study or Trial | No |
NCI- RAZOR | Scientific Study or Trial | No | |
Richard K. Lee, MD | Nothing to disclose | ||
W. Marston Linehan, MD | Nothing to disclose. | ||
Michael A. Liss, MD | Nothing to disclose. | ||
Puneet Masson, MD | Nothing to disclose. | ||
Afshan Ornan ,M.D. | Nothing to disclose. | ||
Gladell Paner, MD | Nothing to disclose. | ||
Glenn M. Preminger, MD | Boston Scientific | Consultant or Advisor | Yes |
Olympus | Meeting Participant or Lecturer | Yes | |
Endourological Society | Leadership Position | Yes | |
UpToDate | Health Publishing | Yes | |
Retrophin | Consultant or Advisor, Meeting Participant or Lecturer | Yes | |
Jay D. Raman, MD | American Kidney Stone Management | Investment Interest | Yes |
Charles D. Scales Jr., MD | NIH/National Institute on Aging | Scientific Study or Trial | Yes |
American Geriatrics Society | Scientific Study or Trial | Yes | |
Society of Urology Chairpersons and Program Directors | Scientific Study or Trial | Yes | |
Pfizer/National Comprehensive Cancer Network | Scientific Study or Trial | Yes | |
Eric A. Singer, MD | Nothing to disclose. | ||
Necole M Streeper, M.D. | Nothing to disclose. | ||
Duong D. Tu, M.D. | Nothing to disclose. | ||
Michael B. Williams, M.D. | Astellas | Consultant or Advisor | Yes |
Jannsen | Consultant or Advisor | Yes | |
Pacific Health Laboratories | Consultant or Advisor | Yes |
Education Council Disclosures:
Name | Company | Role | Financial |
Timothy Charles Brand, M.D. | Nothing to disclose | ||
Peter Robert Carroll MD,MPH | NIH | Scientific Study or Trial | Yes |
Department of Defense | Scientific Study or Trial | Yes | |
Myriad Genetics | Scientific Study or Trial | No | |
AUA Update | Leadership Position | Yes | |
Genomic Health | Scientific Study or Trial | No | |
Sam S. Chang, M.D. | astellas | Consultant or Advisor | Yes |
NIH | Scientific Study or Trial | Yes | |
GLG | Consultant or Advisor | Yes | |
Shelby Englert | Nothing to disclose | ||
Pat Fox Fulgham, MD | Urology Clinics of North Texas | Investment Interest | Yes |
Matthew Thomas Gettman, M.D. | Nothing to disclose | ||
Christina Giffin | Nothing to disclose | ||
Misop Han, M.D. | Nothing to disclose | ||
William C. Hulbert Jr. MD | Nothing to disclose | ||
Douglas A. Husmann MD | Nothing to disclose | ||
Brant Inman, M.D., MS, FRCSC | Dendreon | Scientific Study or Trial | No |
Abbott Laboratories | Scientific Study or Trial | No | |
Genentech Inc | Scientific Study or Trial | No | |
Combat Medical | Consultant or Advisor | Yes | |
Mark L. Jordan MD,FACS | Nothing to disclose | ||
Louis Koncz ,PA-C | American Medical Systems | Meeting Participant or Lecturer | Yes |
Hari K. Koul PhD | Novartis Pharmaceuticals | Consultant or Advisor | Yes |
Urologic Research | Leadership Position | No | |
PLOS one | Leadership Position | No | |
OMICS group | Leadership Position | No | |
Open Access Publishing | Leadership Position, Health Publishing | Yes | |
Martin A. Koyle MD | Nothing to disclose | ||
Tracey Lynn Krupski, MD | Argos | Scientific Study or Trial | No |
NCI- RAZOR | Scientific Study or Trial | No | |
John Stephen Lam MD | Nothing to disclose | ||
Cheryl Taylore Lee, MD | Endo Pharmaceuticals | Scientific Study or Trial | Yes |
Gary Evan Lemack ,M.D. | Astellas | Consultant or Advisor, Meeting Participant or Lecturer | Yes |
Allergan | Consultant or Advisor, Meeting Participant or Lecturer | Yes | |
Medtronic | Consultant or Advisor | Yes | |
Yair Lotan ,M.D. | abbott | Scientific Study or Trial | No |
Danone | Consultant or Advisor, Scientific Study or Trial | Yes | |
Cepheid | Scientific Study or Trial | No | |
Pacific Edge | Scientific Study or Trial | No | |
FKD | Scientific Study or Trial | No | |
MDxHealth | Consultant or Advisor | Yes | |
biocancell | Scientific Study or Trial | No | |
Genomic Health | Scientific Study or Trial | No | |
GenomeDx Biosciences Inc | Scientific Study or Trial | No | |
photocure | Scientific Study or Trial | No | |
Jill A. Macoska PhD | Nothing to disclose | ||
Manoj Monga, MD | Fortec | Other | Yes |
endourology society | Leadership Position | No | |
Victor William Nitti,MD | Astellas | Health Publishing, Scientific Study or Trial | No |
Allergan | Health Publishing, Scientific Study or Trial | No | |
Serenity Pharmeuticals | Investment Interest | Yes | |
Cook Myosite | Scientific Study or Trial | No | |
Christopher Porter, MD | Nothing to disclose. | ||
Gail S. Prins PhD | Nothing to disclose | ||
Jay D. Raman, MD | American Kidney Stone Management | Investment Interest | Yes |
Lee Richstone, MD | Nothing to disclose | ||
Heather Schultz, NP | SUNA | Meeting Participant or Lecturer | Yes |
Karl-Dietrich Sievert, M.D., Ph.D. | AMS | Meeting Participant or Lecturer | Yes |
Medtronics | Meeting Participant or Lecturer, Scientific Study or Trial | Yes | |
Allergen | Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial | Yes | |
Neotract | Meeting Participant or Lecturer | Yes | |
Joseph A. Smith Jr.,M.D. | Nothing to disclose | ||
Sean Patrick Stroup, MD | Intuitive Surgical | Meeting Participant or Lecturer | Yes |
NeoTract | Meeting Participant or Lecturer | Yes | |
Edouard John Trabulsi, MD | GenomeDx | Consultant or Advisor | Yes |
Method of Participation: To claim CME credit/hours of participation for each webcast, the learner must complete to pre-test view the webcast, complete the posttest, passing with 80% accuracy and submit the evaluation.
Estimated time to complete this activity: 1.00 hours
Release Date: June, 2016
Expiration Date: June, 2019
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 CreditTM.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Non-Physician Participation